ARVN
Arvinas, Inc.
NASDAQ · USHealthcareBiotechnology
$8.02+0.12%
Price as of Jul 20, 2026
ARVN financials
Arvinas, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $262.6M | $263.4M | $78.5M | $131.4M |
| Cost of revenue | $5.2M | $0.00 | $0.00 | $0.00 |
| Gross profit | $257.4M | $263.4M | $78.5M | $131.4M |
| Operating expenses | $372.3M | $513.6M | $480.0M | $394.6M |
| Operating income | -$114.9M | -$250.2M | -$401.5M | -$263.2M |
| Net income | -$80.8M | -$198.9M | -$367.3M | -$282.5M |
| EBITDA | -$75.3M | -$191.7M | -$359.7M | -$253.4M |
| Basic EPS | $-1.28 | $-2.77 | $-6.62 | $-5.31 |
| Diluted EPS | $-1.28 | $-2.77 | $-6.62 | $-5.31 |
| Balance sheet | ||||
| Cash & equivalents | $142.9M | $100.5M | $311.7M | $81.3M |
| Total assets | $717.9M | $1.1B | $1.3B | $1.3B |
| Total liabilities | $284.1M | $529.7M | $644.6M | $703.9M |
| Stockholders’ equity | $433.8M | $561.7M | $660.0M | $564.9M |
| Total debt | $8.9M | $9.7M | $3.2M | $5.5M |
| Net debt | -$134.0M | -$90.8M | -$308.5M | -$75.8M |
| Cash flow | ||||
| Operating cash flow | -$273.8M | -$259.3M | -$347.8M | -$273.5M |
| Capital expenditure | -$1.9M | -$1.8M | -$2.9M | -$6.8M |
| Free cash flow | -$275.7M | -$261.1M | -$350.7M | -$280.3M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | -$91.9M | $0.00 | $0.00 | $0.00 |